As the guidelines for the negotiations of future relations between the EU and the UK are approved, allowing the progression of Brexit talks, pharma, biotech and manufacturing industry leaders give their opinions on the transition.
Brexit opinion
The Association of the British Pharmaceutical Industry (ABPI) has welcomed the move to the next phase of talks. “The EU Council’s agreement to progress to future partnership talks and their approval of a transition period is welcome news,” said Mike Thompson, CEO of the ABPI. “Every month, our industry supplies 45 million packs of medicine to Europe and 37 million come back the other way. Subject to the final withdrawal agreement, our members now know they will have until December 2020 to do all they can to make sure that these medicines continue to get to patients.”